Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Lisa H. Butterfield, Yana G. Najjar
Nature reviews. Immunology (2023) Vol. 24, Iss. 6, pp. 399-416
Closed Access | Times Cited: 96

Showing 26-50 of 96 citing articles:

Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer
Xiaoxuan Tao, Qichang Gao, Yiyang Chen, et al.
Strahlentherapie und Onkologie (2025)
Open Access
The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers
Thulo Molefi, Lloyd Mabonga, Rodney Hull, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 382-382
Open Access
Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice
Zhenzhen Wen, Tong Liu, Xutao Xu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Immunity‐Modulating Metal‐Based Nanomaterials for Cancer Immunotherapy
Xing Sun, Xican Xu, Fengying Li, et al.
Advanced Functional Materials (2025)
Closed Access
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit
Kristen E. Pauken, Omar Alhalabi, Sangeeta Goswami, et al.
Cancer Cell (2025)
Closed Access
Balancing immunotherapy and corticosteroids in cancer treatment: dilemma or paradox?
Alessandro Ottaiano, Mariachiara Santorsola, Maurizio Capuozzo, et al.
The Oncologist (2025) Vol. 30, Iss. 3
Open Access
Neoantigen vaccines: advancing personalized cancer immunotherapy
Alaa A. A. Aljabali, Yassmen Hamzat, Alaa Alqudah, et al.
Exploration of Immunology (2025) Vol. 5
Open Access
Innovative Organic Core–Nonmagnetic Shell Nanoconstructs: Pioneering Precision in Cancer Theranostics
Amrita Arup Roy, Rahul Pokale, Anoushka Mukharya, et al.
(2025), pp. 415-449
Closed Access
Alterations in genomic features and the tumour immune microenvironment predict immunotherapy outcomes in advanced biliary tract cancer patients
Chenjun Huang, Zhiquan Qiu, Honglian Huang, et al.
British Journal of Cancer (2025)
Closed Access
Cancer Immunology and Immunotherapy
Guang-Rui Wang, Lei‐Ming Cao, Zhenyu Xu, et al.
(2025), pp. 3-18
Closed Access
Chemoimmunotherapy synergism: mechanisms and clinical applications
Rahaman Shaik, Sai Manasa Chittepu, Meghana Tarapatla, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review)
Toru Hiraga
International Journal of Oncology (2024) Vol. 64, Iss. 4
Closed Access | Times Cited: 4
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, et al.
Seminars in Liver Disease (2024) Vol. 44, Iss. 02, pp. 159-179
Open Access | Times Cited: 4
Dual‐Functional Nanodroplet for Tumor Vasculature Ultrasound Imaging and Tumor Immunosuppressive Microenvironment Remodeling
Yuan Liang, Siyan Zhang, Dingyi Wang, et al.
Advanced Healthcare Materials (2024)
Closed Access | Times Cited: 4
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma
Aaron S. Mansfield, Jun Vivien Yin, Penelope A. Bradbury, et al.
Lung Cancer (2024) Vol. 195, pp. 107928-107928
Closed Access | Times Cited: 4
Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
Ran Ni, Zhiming Hu, Ran Tao
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117430-117430
Open Access | Times Cited: 4
Immunomodulatory metal-based biomaterials for cancer immunotherapy
Kangzhi Yuan, Cai Zhang, Xiang-Ying Pan, et al.
Journal of Controlled Release (2024) Vol. 375, pp. 249-268
Closed Access | Times Cited: 4
Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity
Dianying Zhang, Jingjing Zhao, Yujing Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Editorial: Enhancing innate immunity in combination therapy for solid tumors
David Pejoski
Frontiers in Immunology (2025) Vol. 15
Open Access
Mesoporous dual-atom nanozyme induced cuproptosis and apoptosis for boosting immunogenic cell death along with reprogramming tumor immune-suppressive microenvironment
Yunhao Wang, Lei Ding, Zhan Lin, et al.
Chemical Engineering Journal (2025) Vol. 506, pp. 160294-160294
Closed Access
Research Progress on the Efficacy of Immune Checkpoint Inhibitor Combination Therapy in Advanced Non-Small Cell Lung Cancer
普艳 马
Hans Journal of Biomedicine (2025) Vol. 15, Iss. 02, pp. 265-272
Closed Access
Potentiation of immune checkpoint blockade with a pH-sensitizer as monitored in two pre-clinical tumor models with acidoCEST MRI
Richard Tran, Tianzhe Li, Jorge de la Cerda, et al.
British Journal of Cancer (2025)
Closed Access
The immunopeptidome of colon cancer cells treated with topoisomerase inhibiting drug reveals differential as well as common endogenous protein sampling and display of MHC I-associated peptides
Deepa Bedi, Md. Imtaiyaz Hassan, Alehegne Yirsaw, et al.
Molecular & Cellular Oncology (2025) Vol. 12, Iss. 1
Open Access
Personalized Approaches to Lung Cancer Treatment: A Review of Targeted Therapies, Pharmacogenomics, and Combination Strategies
M. Tabrizi Namini, G. Bhagya, Manjari Sharma
Aspects of Molecular Medicine (2025), pp. 100073-100073
Open Access
Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy
Haimeng Yuan, Yao Chen, Yuting Hu, et al.
Journal of Pharmaceutical Investigation (2025)
Closed Access

Scroll to top